Jacob S Aday, PhD
Research Investigator, Anesthesiology
Research Fellow, Internal Medicine
[email protected]

Available to mentor

Jacob S Aday, PhD
Research Investigator
  • About
  • Qualifications
  • Research Overview
  • Recent Publications
  • About

    Jacob S. Aday, Ph.D. is a Research Investigator in the Department of Anesthesiology, with appointments in the Chronic Pain and Fatigue Research Center (CPFRC) as well as the Michigan Psychedelic Center (M-PsyC). He completed his undergraduate and master's degrees in Psychology at Northern Michigan University, where he worked in Dr. Adam Prus’s Neuropsychopharmacology Lab and Dr. Joshua Carlson’s Cognitive Affective Behavior and Integrative Neuroscience (CABIN) Lab. During his doctoral training, Jake was mentored by Drs. Christopher Davoli and Emily Bloesch at Central Michigan University, where they established a productive program of research centered on the emerging field of ‘psychedelic science’. During this time, he was also recruited by Drug Science, the leading independent scientific body on drugs in the UK, to be an honorary research assistant and study under Professor David Nutt. Jake then joined the Translational Psychedelic Research Program (TrPR) at the University of California, San Francisco (UCSF) as a postdoctoral researcher in 2021. There, he was mentored by Dr. Joshua Woolley on how to design, implement, and interpret complex psychedelic clinical trials. As a Research Investigator in the Department of Anesthesiology, Dr. Aday is interested in the cognitive and social effects of psychedelics, improving research methodology and safety with the drugs, and examining the potential applications of psychedelic therapy for chronic pain.

    • PhD
      Central Michigan University, Mount Pleasant, MI, 2021
    • MS
      Northern Michigan University, Marquette, MI, 2017
    • BS
      Northern Michigan University, Marquette, MI, 2015
    Research Overview

    • Psychedelics
    • Social Cognition
    • Emotion
    • Chronic Pain

    Recent Publications See All Publications
    • Presentation
      Challenges in Trial Design for Psychedelic-Assisted Therapies
      Aday J. 2023 Nov;
    • Journal Article
      Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry
      Aday JS, Barnett BS, Grossman D, Murnane KS, Nichols CD, Hendricks PS. Psychedelic Medicine, 2023 Sep 1; 1 (3): 150 - 165. DOI:10.1089/psymed.2023.0013
    • Presentation
      Psychedelic science: An overview of contemporary directions
      Aday J. 2023 Sep;
    • Additional Scholarship
      Inverse: Psychedelic therapy may be coming to a headset near you
      Glick M. 2023 Jul;
    • Journal Article
      Emerging Challenges for Psychedelic Therapy.
      Aday JS, Carhart-Harris RL, Woolley JD. JAMA Psychiatry, 2023 Jun 1; 80 (6): 533 - 534. DOI:10.1001/jamapsychiatry.2023.0549
      PMID: 37074690
    • Journal Article
      Eye-size effects in the dot-probe task: Greater sclera exposure predicts delayed disengagement from fearful faces.
      Aday JS, Fang L, Carlson JM. PLoS One, 2023 18 (5): e0285839 DOI:10.1371/journal.pone.0285839
      PMID: 37195990
    • Additional Scholarship
      Podcast: Learning with Lowell: Psychedelic Zeitgeist: Past, Present, and Future – Dr. Jacob Aday
      Thomposon L. 2023 May;
    • Additional Scholarship
      Wired: Scientists Gave People Psychedelics—and Then Erased Their Memory
      Love S. 2023 May;